Patents Assigned to The Brigham and Women's Hospital, Inc.
  • Patent number: 10369152
    Abstract: Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 6, 2019
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Paul B. Yu, Jana Bagarova, Devaveena Dey
  • Publication number: 20190231779
    Abstract: Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Paul B. Yu, Jana Bagarova, Devaveena Dey
  • Publication number: 20190225683
    Abstract: Described herein are novel compositions, targeted therapeutic methods, and assays for neutralizing and/or inhibiting the activity of “oxazole-containing (OxC) compounds,” to prevent or delay the onset of epithelial barrier dysfunction and chronic inflammation associated with various disorders, such as colitis.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 25, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Shankar S. IYER, Thomas GENSOLLEN, Amit GANDHI
  • Publication number: 20190225701
    Abstract: The compositions and methods described herein are based, in part, on the discovery that regulatory B cells (Bregs) differentially express a specific set of coinhibitory molecules, including TIGIT, LAG-3, PD-1, CTLA4, and TIM-3. The data described herein indicate that TIGIT is required for both Breg-mediated tolerance maintenance at the steady state, and inflammation restraint during autoimmune and inflammatory diseases. Accordingly, provided herein are compositions and methods targeting coinhibitory molecules, such as TIGIT, LAG-3, PD-1, CTLA4, and TIM-3, in B cells, as novel therapeutic strategies for modulating immune suppression and treating diseases mediated or impacted by immune suppression mechanisms, such as autoimmune diseases and cancers.
    Type: Application
    Filed: September 26, 2017
    Publication date: July 25, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. Kuchroo, Sheng XIAO
  • Publication number: 20190209090
    Abstract: Gastric resident electronics, devices, systems, and related methods are generally provided. Some embodiments comprise administering (e.g., orally) an (electronic) resident structure to a subject (e.g., a patient) such that the (electronic) resident structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before exiting said location internal to the subject. In some embodiments, the resident structure is a gastric resident electronic. That is to say, in some embodiments, the resident structure is configured for relatively long gastric residence and comprises an electronic component. In some embodiments, the structures and components described herein may comprise one or more components configured for the delivery of an active substance(s) (e.g., a pharmaceutical agent) to the subject.
    Type: Application
    Filed: November 28, 2018
    Publication date: July 11, 2019
    Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Robert S. Langer, Carlo Giovanni Traverso, Yong Lin Kong
  • Publication number: 20190209603
    Abstract: Provided herein are methods for reducing levels of blood cholesterol, low-density lipoprotein (LDL), and/or the treatment of diseases associated with high cholesterol, hyperlipidemia, dyslipidemia, or high levels of low-density lipoprotein (LDL), wherein the methods comprise administering a DRP1 inhibitor to a subject in need thereof. In certain embodiments, the subject is selected for treatment as described herein when the subject exhibits intolerance to conventional statin therapy. Also contemplated herein are the use of DRP1 inhibitors in the treatment of cancer and inflammatory disease.
    Type: Application
    Filed: September 12, 2017
    Publication date: July 11, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Elena AIKAWA, Maximillian ROGERS, Masanori AIKAWA
  • Patent number: 10345297
    Abstract: The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: July 9, 2019
    Assignees: Howard Hughes Medical Institute, The Brigham & Women's Hospital, Inc.
    Inventors: Jonathan S. Marvin, Loren Looger, Richard T. Lee, Eric Schreiter
  • Patent number: 10343163
    Abstract: A system and method are provided for harvesting target biological substances. The system includes a substrate and a first and second channel formed in the substrate. The channels longitudinally extending substantially parallel to each other. A series of gaps extend from the first channel to the second channel to create a fluid communication path passing between a series of columns with the columns being longitudinally separated by a predetermined separation distance. The system also includes a first source configured to selectively introduce into the first channel a first biological composition at a first channel flow rate and a second source configured to selectively introduce into the second channel a second biological composition at a second channel flow rate. The sources are configured to create a differential between the first and second channel flow rates to generate physiological shear rates along the second channel that are bounded within a predetermined range.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: July 9, 2019
    Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College, Vilnius University
    Inventors: Joseph Italiano, Linas Mazutis, Jonathan N. Thon, David A. Weitz
  • Publication number: 20190201496
    Abstract: Provided herein, in some aspects, are compositions and methods to inhibit AFP interactions with ?2M and/or Class I-related molecule interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate AFP interactions with ?2M and/or Class I-related molecule in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels is desired to increase immunosuppression or enhance organ regeneration.
    Type: Application
    Filed: September 14, 2017
    Publication date: July 4, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., UNIVERSITY OF OSLO
    Inventors: Richard S. BLUMBERG, Michal PYZIK, Amit GANDHI, Inger SANDLIE, Kine Marita Knudsen SAND, Jan Terje ANDERSEN
  • Publication number: 20190201524
    Abstract: The technology described herein relates to compositions and methods for enhancing the immune response and/or reducing T cell tolerance in a subject. In some embodiments, the technology described herein relates to administering inhibitors of two or more of CEACAM1, PD1, and/or LAP to, e.g., synergistically reduce T cell tolerance.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 4, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard S. BLUMBERG, Yu-Hwa HUANG
  • Publication number: 20190192582
    Abstract: Disclosed are methods and compositions for the prevention and treatment of food allergy. In particular, described herein are microbial consortia, including minimal microbial consortia, that can prevent and/or cure food allergy. In certain embodiments, the consortia comprise certain members of the taxa Clostridiales and/or Bacteroidetes.
    Type: Application
    Filed: March 5, 2019
    Publication date: June 27, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Talal A. Chatila, Lynn Bry, Georg Gerber, Azza Abdel-Gadir, Rima Rachid
  • Patent number: 10329315
    Abstract: The invention provides, inter alia, immunoinhibitory glycosphingolipids and immunoinhibitory alpha-galactosylceramides and compositions and preparations thereof, and methods of use thereof including in the treatment of conditions characterized by increased iNKT cells and/or activity.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: June 25, 2019
    Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
    Inventors: Dennis L. Kasper, Dingding An, Sungwhan Oh, Richard S. Blumberg, Torsten Olszak, Joana F. Neves
  • Publication number: 20190183964
    Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
    Type: Application
    Filed: July 9, 2018
    Publication date: June 20, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
    Inventors: Richard S. BLUMBERG, Timo RATH, Kristi BAKER, Adam MEZO, Zachary TAYLOR, Kevin MCDONNELL, Rosa Maria Silva Garcia GRENHA
  • Publication number: 20190185559
    Abstract: The invention provides therapeutic combinations comprising an agent that inhibits Notch signaling and an agent that inhibits B cell receptor signaling, and methods of using such agents to inhibit the survival or proliferation of a neoplastic cell.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 20, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., THE GENERAL HOSPITAL CORPORATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: RYAN J.H. RUSSELL, BRADLEY E. BERNSTEIN, JON ASTER, WARREN S. PEAR
  • Publication number: 20190175500
    Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.
    Type: Application
    Filed: February 15, 2019
    Publication date: June 13, 2019
    Applicants: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Andrew Bellinger, Shiyi Zhang, Carlo Giovanni Traverso, Robert S. Langer, Stacy Mo, Tyler Grant, Mousa Jafari, Dean Liang Glettig, Angela DiCiccio, Lowell L. Wood, JR., Philip A. Eckhoff
  • Publication number: 20190177426
    Abstract: Embodiments described herein provide anti-fibulin-3 antibodies, recombinant proteins that bind specifically to fibulin-3, compositions and the treatment methods comprising these antibodies and recombinant proteins.
    Type: Application
    Filed: January 30, 2019
    Publication date: June 13, 2019
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Mariano S. VIAPIANO, Nandhu Mohan SOBHANA, Ennio Antonio CHIOCCA
  • Patent number: 10318707
    Abstract: Apparatus, systems, and methods are provided for assessing clot activity in blood under various conditions in vitro. The apparatus includes a plurality of test receptacles that receive the blood, at least one flow generating mechanism in communication with the test receptacles, and a clot detector configured to analyze an amount of clot formation that occurs within the blood in each receptacle. Blood contacting surfaces of a first subset of the test receptacles are coated with a first surface substrate and blood contacting surfaces of a second subset of the test receptacles are coated with a different second surface substrate. The flow generating mechanism is configured to generate a first blood flow rate through a third subset of the test receptacles and to generate a different second blood flow rate through a fourth subset of the test receptacles.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: June 11, 2019
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Kumaran Kolandaivelu, Elazer R. Edelman
  • Patent number: 10314917
    Abstract: Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or NMR contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging. They are targeted to sites of, or associated with, inflammation caused by a disease, disorder; trauma, chemotherapy or radiation.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: June 11, 2019
    Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of Technology, The Trustees of Columbia University in the City of New york
    Inventors: Omid C. Farokhzad, Xueqing Zhang, Xiaoyang Xu, Nazila Kamaly, Mingming Ma, Pedro M. Valencia, Robert S. Langer, Ira Tabas, Gabrielle Beth Fredman
  • Publication number: 20190169290
    Abstract: Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject.
    Type: Application
    Filed: June 29, 2018
    Publication date: June 6, 2019
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Richard S. Blumberg, Kristi Baker, Timo Rath
  • Patent number: 10308986
    Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 4, 2019
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., THE TECHNICAL UNIVERSITY OF DENMARK, KGS
    Inventors: Zoltan I. Szallasi, Andrea L. Richardson, Nicolai J. Birkbak, Zhigang Wang